Cadazolid for treatment of Clostridium difficile-associated diarrhoea

NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
Clostridium difficile is a bacterium that infects the gut and causes diarrhoea. It usually affects people who have recently taken antibiotics and it can cause serious bowel problems if left untreated. The bacterium is easily spread by direct contact with infected people or surfaces. Cadazolid is a new antibiotic that is taken by mouth as a liquid. Some studies have suggested that this drug can help to treat Clostridium difficile-associated diarrhoea, and more studies are trying to show how well cadazolid works. If cadazolid is licensed for use in the UK, it could offer a new treatment option for this patient group.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/cadazolid-for-treatment-of-clostridium-difficile-associated-diarrhoea/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Clostridium difficile; Diarrhea; Oxazolidinones; Anti-Bacterial Agents

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000680

Date abstract record published
25/05/2016